human epidermal growth factor receptor (her) family plays an important role in various types of cancers. as a result, antibodies against her and the mechanism of antigen-antibody binding action are under active investigation. we previously constructed a single-chain variable fragment (scfv) against her2, i.e. anti-her2 scfv, for expressing in the escherichia coli . in the present study, we repo...

Convincing epidemiologic evidence indicates that physical activity is inversely associated with breast cancer risk. Whether this association varies by the tumor protein expression status of the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), or p53 is unclear. We evaluated the effects of recreational physical activity on risk of invasive brea...

The calcium-activated chloride channel Ano1 (TMEM16A) is overexpressed in many tumors. However, conflicting data exist regarding the role of Ano1 in cell proliferation. Here, we performed immunohistochemistry to investigate the expression of Ano1 and Ki67 in 403 patients with breast cancer, and analyzed the association between the expression of Ano1 and Ki67 in breast cancer subtypes categorize...

The overexpressed HER2 (human epidermal growth factor receptor 2) is a valuable therapeutic target. Precise assessment of HER2 status is thus crucial in the treatment of breast cancer. In this study, formalin-fixed, paraffin-embedded samples of tumors from 304 breast cancer patients who underwent curative surgery procedures between 2011 and 2014 were tested by immunohistochemistry (IHC) as a pr...

PURPOSE Preclinical studies have shown that human epidermal growth factor receptor 2 (HER2) status is associated with resistance to radiotherapy (RT). In this study, we evaluated the overall survival of a T1N0M0 breast cancer cohort in Korea according to the use of RT and the HER2 status. METHODS We analyzed data collected from 11,552 patients with invasive breast cancer who were enrolled in ...

The efficacy of neoadjuvant chemotherapy (NAC), as measured by the pathological complete response (pCR), varies between molecular subtypes in breast cancer (BC). Oestrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative patients tend to have lower pCR rates. transcription progesterone (PR) is dependent on ER therefore PR negativity may suggest an erroneous oestrogen sign...

PURPOSE Acquired endocrine resistance in estrogen receptor (ER)alpha+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer has been associated with modest adaptive increases in HER2, although exactly how aberrant HER2 signaling affects the ERalpha pathway is poorly understood. We investigated (a) whether the epidermal growth factor receptor/HER2 inhibitor lapatinib could rest...

Expression of the hormone receptors (estrogen receptor (ER) and progesterone receptor (PR)) as well as overexpression / amplification of the human epi-dermal growth factor receptor-2 (HER2) have not only been identified as important prognostic factors among patients with breast cancer. They have also been characterized as essential predictive factors for benefit derivable from endocrine treatme...

The human epidermal growth factor receptor 2/neuregulin (HER2/neu) receptor is overexpressed in highly malignant mammary and ovarian tumors and correlates with a poor prognosis. It is a target for therapy; humanized monoclonal antibodies to HER2 have led to increased survival of patients with HER2/neu-positive breast cancer. As a first step in the design of an oncolytic herpes simplex virus abl...

Pathological complete response (pCR) is a surrogate biomarker of survival in Human Epidermal Growth Factor Receptor 2-positive (HER2+) breast cancer (BC) and more likely to occur hormonal receptor (HR) negative (-). In the early efficacy safety analysis ZoNAnTax trial, 4 cycles doxorubicin/cyclophosphamide with ZOL, followed by docetaxel trastuzumab ZOL prior surgery induced similar pCR rates H...